LADENBURG THALM/SH SH upgraded shares of Palisade Bio (NASDAQ:PALI – Free Report) to a strong-buy rating in a research note published on Thursday,Zacks.com reports.
PALI has been the subject of a number of other reports. HC Wainwright assumed coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price objective for the company. Stifel Nicolaus assumed coverage on Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Wall Street Zen lowered Palisade Bio from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Wolfe Research began coverage on Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Palisade Bio presently has a consensus rating of “Buy” and an average target price of $10.20.
Get Our Latest Analysis on Palisade Bio
Palisade Bio Stock Up 5.0%
Palisade Bio (NASDAQ:PALI – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Equities analysts expect that Palisade Bio will post -0.21 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Palisade Bio
Several institutional investors and hedge funds have recently made changes to their positions in PALI. CTC Alternative Strategies Ltd. acquired a new position in Palisade Bio in the first quarter worth $31,000. Bank of America Corp DE raised its position in Palisade Bio by 181.1% during the first quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock valued at $345,000 after acquiring an additional 126,977 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Palisade Bio by 1.4% in the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after purchasing an additional 149,118 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of Palisade Bio by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock valued at $3,963,000 after acquiring an additional 260,000 shares during the last quarter. Finally, Orbimed Advisors LLC raised its position in shares of Palisade Bio by 24.7% in the first quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock valued at $4,083,000 after purchasing an additional 461,580 shares during the period. 11.79% of the stock is owned by institutional investors and hedge funds.
Palisade Bio Company Profile
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
Further Reading
- Five stocks we like better than Palisade Bio
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
